Advocacy intelligence hub — real-time data for patient organizations
The University of Queensland — PHASE2
Seoul National University Hospital
Eighth Affiliated Hospital, Sun Yat-sen University
Vancouver Coastal Health — PHASE1
University College, London — NA
Bin Cao — PHASE4
Bin Cao — PHASE4
Research Center Borstel
Kevin Winthrop — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
ARIKAYCE
Insmed
Rifadin I.V.
Hoechst Marion Roussel
Patient Assistance Programs2
Mycobutin
Adria Laboratories, Inc.
SIRTURO
Janssen Research & Development, LLC
SIRTURO
(bedaquiline)Orphan drugstandardJanssen Research & Development, LLC
12.1 Mechanism of Action Bedaquiline is a diarylquinoline antimycobacterial drug [see Microbiology (12.4) ] .
Mycobutin
(Rifabutin)Orphan drugstandardAdria Laboratories, Inc.
Rifamycin Antimycobacterial [EPC]
Mechanism of Action Rifabutin inhibits DNA-dependent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis but not in mammal...
Arikayce
(liposomal amikacin)Orphan drugacceleratedInsmed Incorporated
Aminoglycoside Antibacterial [EPC]
12.1 Mechanism of Action ARIKAYCE is an antibacterial drug [see Microbiology (12.4) ].
Browse all Pulmonary non-tuberculous mycobacterial infection news →
Andrej Spec, MD
Washington University School of Medicine
📍 SAINT LOUIS, MO
Kevin L Winthrop, MD, MPH
Oregon Health and Science University
📍 PORTLAND, OR
Edwin Rubel, PhD
Oricula Therapeutics
Steven M Holland, M.D.
National Institutes of Health Clinical Center (CC)
Morounfolu Olugbosi, MD
Global Alliance for TB Drug Development
Francesca Conradie
Isango Lethemba TB Research Unit
View all Pulmonary non-tuberculous mycobacterial infection specialists →